HYTERA
5.7.2022 15:31:03 CEST | Business Wire | Press release
Hytera, a leading global provider of professional communications technologies and solutions, together with its subsidiaries Sepura and Teltronic, won awards in 5 categories at the International Critical Communications Awards (ICCAs) 2022 held in Vienna, Austria. The ICCAs, presented by The Critical Communications Association (TCCA), are the most prestigious awards in critical communications celebrating the very best of the sector across a variety of verticals and recognizing those who have made significant and individual contributions to the critical communications industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220705005515/en/
Hytera was firstly awarded “Best Use of Critical Communications in Transport ” for a Sri Lanka Railway (SLR) Telecommunications Project. This project enabled Hytera’s 3GPP-compliant MCS Solution to interconnect the SLR sites and provide railway personnel with real-time access to critical data. This allowed them to better serve passengers and provide a smooth and safe operation for train drivers by improving punctuality and reducing railway accidents.
Sepura also claimed an ICCA award for “Best Use of Critical Communications in Mining, Oil & Gas ” for the AutoMate App SPACE Application and SCG22 Mobile Radio which was part of the National Wireless Mining Solution. The solution contributed to the operational performance and safety of staff by enabling radio automation through geo-fencing and situational triggers in iron ore mines in Australia.
The SCU3, Sepura’s latest broadband vehicle device, won “Best MX-C Device of the Year ”. This technology aroused considerable interests amongst professional communication users looking for future-proof, powerful data capability to enhance their communications solutions.
Sepura’s Senior Specialist Diana Ball was recognized for her “Outstanding Contribution to Critical Communications ” for the development of TETRA standards that are still trusted by users to ensure interoperability between suppliers.
Teltronic’s EDESUR project was next awarded “Best Use of Critical Communications in Utilities” . The NEBULA TETRA infrastructure allowed a private electricity distribution company in Argentina to realize the real-time monitoring and fault detection of a power distribution network, and further improve company management and operational efficiency thanks to Teltronic’s unique SDM (Synchronous Data Management) technology.
In addition to securing these awards, Hytera Group was also shortlisted for a number of additional categories including:
Best MC-X Device of the Year
Hytera PDM680 Rugged MCS Radio
Teltronic RTP-800, the First MCX Cab Radio for Transport
Best MC-X solutions of the year
Sepura SCU3 Broadband Vehicle Device
Best TETRA Device of the Year
Hytera PTC680 Multi-mode Radio
Sepura SCG22 Mobile TETRA Radio
Best Use of Advanced Technology
Hytera AI-based Noise Cancellation for Two-way Radios
Best Use of Critical Communications in Public Safety
Teltronic: RESCAN, Reliability and Maximum Coordination in the Fight against the Volcano
Best Use of Critical Communications in Transport
Hytera: Kazakhstan Railway Runs Safely and Efficiently with TETRA Communications System
Emerging Technology, Product or Solutions
Hytera PNC560, World’s First 5G MCPTT Device
Recently Hytera has released a number of innovations from its wide range of product lines, including the latest H-Series DMR Radios, Body-worn Cameras, PTToC Radios & MCS Radios, Multi-mode Rugged Radio and 5G Xsecure Rugged Device. Also the newly launched Hytera Convergence-Native Solutions (including HyTalk, HyTalk Pro and HyTalk MC), composed of different modules, integrates existing network infrastructures, unifies the network core and the communication platform, and provides open API for new service deployment.
With cutting-edge critical communication technologies, Hytera will continue to bring value to global customers leveraging its technologies and professionals.
For more information about Hytera at ICCAs 2022, please visit: https://www.hytera.com/en/media-center/event/hytera-group-won-international-critical-communication-awards.html
View source version on businesswire.com: https://www.businesswire.com/news/home/20220705005515/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom